SRR934883
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 19.415243101182654
- age_years
- 47
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.579
- MYC_TARGETS_V1+0.563
- ANGIOGENESIS+0.554
- MYC_TARGETS_V2+0.539
- TNFA_SIGNALING_VIA_NFKB+0.520
- DNA_REPAIR+0.518
- INTERFERON_GAMMA_RESPONSE+0.513
- E2F_TARGETS+0.512
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.507
- IL6_JAK_STAT3_SIGNALING+0.502
Top 10 suppressed
- KRAS_SIGNALING_DN-0.424
- HEDGEHOG_SIGNALING-0.301
- PANCREAS_BETA_CELLS-0.260
- SPERMATOGENESIS-0.247
- WNT_BETA_CATENIN_SIGNALING-0.200
- ESTROGEN_RESPONSE_EARLY-0.137
- UV_RESPONSE_DN-0.112
- MITOTIC_SPINDLE-0.079
- BILE_ACID_METABOLISM-0.045
- MYOGENESIS-0.025
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4B4647B5-1964-49A9-AC25-89AB4A669341 | — | — | 0.976 |
| 2 | 788A8487-6A02-4BF5-8E84-16BE5D92BF0F | — | — | 0.971 |
| 3 | CC9815B3-88D0-4376-B96F-B979E1FBD0C7 | — | — | 0.971 |
| 4 | FFECD0E9-70C2-44BD-B0B4-E8C4B60B793A | — | — | 0.969 |
| 5 | A462D32E-3A6A-4E00-A4A7-BAF374D6009C | — | — | 0.966 |
| 6 | 8DA59514-8B25-493E-B226-818F2521B5D5 | — | — | 0.966 |
| 7 | B9535625-504A-4FCD-B341-2985AE72508A | — | — | 0.963 |
| 8 | 3E499D12-B08A-491C-98C6-19EA420BDC99 | — | — | 0.961 |
| 9 | 4A54E284-9902-4E4C-A5BC-1BF144106EA3 | — | — | 0.961 |
| 10 | A2170829-B80C-49F2-8FB6-39B8ACFB27CB | — | — | 0.960 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.579 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.563 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.554 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.539 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.520 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.518 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.513 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.512 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.507 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.502 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.459 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.453 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.451 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.448 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.407 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.399 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.398 | Inavolisib | — uncovered |
| COAGULATION | 0.397 | Binimetinib | — uncovered |
| COMPLEMENT | 0.386 | Inavolisib | — uncovered |
| HYPOXIA | 0.378 | Idelalisib | — uncovered |